A hypoxia responsive silicon phthalocyanine containing naphthquinone axial ligands for photodynamic therapy activity

J Inorg Biochem. 2023 Feb:239:112078. doi: 10.1016/j.jinorgbio.2022.112078. Epub 2022 Nov 21.

Abstract

A liposome loaded‑silicon (IV) phthalocyanine (SiPc) containing naphthoquinone axial ligands as hypoxia-responsive a prodrug-like moieties (Prodrug-SiPc), is herein reported. With the help of computational methods, this study assessed the photophysical, photochemical and electrochemical redox properties of the Prodrug-SiPc to elucidate the relationship between material structure and properties. The attachment of the axial quinoid moieties endowed the Prodrug-SiPc with Type I/II photochemical and prodrug-like properties. Following liposomal encapsulation, the therapeutic efficacy of Prodrug-SiPc-liposomes was investigated against Michigan Cancer Foundation-7 (MCF-7) and Henrietta Lacks (Hela) cancer cells as in vitro cancer models and revealed that the as-synthesized Prodrug-SiPc-liposomes are potential photodynamic therapy (PDT) drug candidates. The Prodrug-SiPc-liposome takes full advantage of the hypoxic microenvironment of tumors - a side effect PDT - to trigger therapy, resulting in significantly enhanced efficacy compared to typical PDT. This work highlights the importance of multiple characteristics in designing new and effective photosensitizer candidates.

Keywords: Combination therapy; Hypoxia-response; Photodynamic therapy; Phthalocyanines; Prodrugs; cancer cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Hypoxia
  • Ligands
  • Liposomes
  • Neoplasms* / drug therapy
  • Photochemotherapy* / methods
  • Photosensitizing Agents / chemistry
  • Prodrugs* / chemistry
  • Tumor Microenvironment

Substances

  • N-succinimidyl-5-iodo-3-pyridinecarboxylic acid
  • silicon phthalocyanine
  • Liposomes
  • Ligands
  • Prodrugs
  • Photosensitizing Agents